Page 17 - Read Online

Mini et al. Cancer Drug Resist 2020;3:225-31 I http://dx.doi.org/10.20517/cdr.20220.10 Page 231

Resist 2019;2:225-41.
13. Tarantino P, Trapani D, Morganti S, Ferraro E, Viale G, et al. Opportunities and challenges of implementing pharmacogenomics in
cancer drug development. Cancer Drug Resist 2019;2:43-52.
14. Hierro C, Matos I, Martin-Liberal J, Ochoa de Olza M, Garralda E. Agnostic-histology approval of new drugs in oncology: are we
already there? Clin Cancer Res 2019;25:3210-19.
15. Renfro LA, An MW, Mandrekar SJ. Precision oncology: a new era of cancer clinical trials. Cancer Lett 2017;387:121-6.
16. Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, et al. Comprehensive characterization of cancer driver genes and
mutations. Cell 2018;173:371-85.e18.
17. De Mattia E, Roncato R, Dalle Fratte C, Ecca F, Toffoli G, et al. The use of pharmacogenetics to increase the safety of colorectal
cancer patients treated with fluoropyrimidines. Cancer Drug Resist 2019;2:116-30.
®
18. CPIC Guideline for Fluoropyrimidines and DPYD November 2018 & January 2020 Updates. Available from: https://cpicpgx.org/
guidelines/guideline-for-fluoropyrimidines-and-dpyd/ [Last accessed on 12 Feb 2020]
19. Franca R, Zudeh G, Pagarin S, Rabusin M, Lucafò M, et al. Pharmacogenetics of thiopurines. Cancer Drug Resist 2019;2:256-70.
20. Clinical pharmacogenetics implementation consortium guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes:
2018 update (November 2018). Available from: https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/ [Last accessed on
12 Feb 2020]
21. Abaji R, Krajinovic M. Pharmacogenetics of asparaginase in acute lymphoblastic leukemia. Cancer Drug Resist 2019;2:242-55.
22. Shek D, Read SA, Ahlenstiel G, Piatkov I. Pharmacogenetics of anticancer monoclonal antibodies. Cancer Drug Resist 2019;2:69-81.
23. Murthy P, Muggia F. PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues. Cancer Drug
Resist 2019;2:665-79.
24. Kumar S, Kushwaha PP, Gupta S. Emerging targets in cancer drug resistance. Cancer Drug Resist 2019;2:161-77.
25. Belizario JE, Loggulo AF. Insights into breast cancer phenotying through molecular omics approaches and therapy response. Cancer
Drug Resist 2019;2:527-38.
26. Ravegnini G, Hrelia P, Angelini S. Somatic pharmacogenomics of gastrointestinal stromal tumor. Cancer Drug Resist 2019;2:107-15.
27. Alonso-Peña M, Sanchez-Martin A, Sanchon-Sanchez P, Soto-Muñiz M, Espinosa-Escudero R, et al. Pharmacogenetics of
hepatocellular carcinoma and cholangiocarcinoma. Cancer Drug Resist 2019;2:680-709.